Toolgen announced on the 12th that it has hired Vice President Baekseung Lee as Chief Technology Officer (CTO), who will lead the research and development of next-generation gene editing and immune cell treatments.
This CTO participated in research related to immune cells and gene editing at ‘Bluebird Bio’, a bio company listed on NASDAQ. At the time, it was evaluated as having contributed to numerous patent applications and obtaining approval from the U.S. Food and Drug Administration (FDA).
He oversaw the development of COVID-19 antibody treatments and diagnostic kits at KOSDAQ-listed CancerRop (currently DX&VX), and also led the research and development of next-generation immune cell treatments at MJ Cell Bio. Toolgen expects to strengthen its technological capabilities and research and development competitiveness in the global bio market by recruiting this CTO.
Toolgen CEO Lee Byung-hwa said, “With the recruitment of new CTO Baek-seung Lee, we will be able to accelerate the development of next-generation treatments.”
Source: kormedi.com
